Guggenheim Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $5.
Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $5.